CRBP
NASDAQ HealthcareCorbus Pharmaceuticals Holdings, Inc. - Common Stock
Biotechnology
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
๐ Market Data
| Price | $8.80 |
|---|---|
| Volume | 228,790 |
| Market Cap | 163.04M |
| Beta | 2.560 |
| RSI (14-Day) | 58.0 |
| 200-Day MA | $10.08 |
| 50-Day MA | $9.11 |
| 52-Week High | $20.56 |
| 52-Week Low | $7.12 |
| Forward P/E | -1.73 |
| Price / Book | 1.24 |
๐ฏ Investment Strategy Scores
CRBP scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (95/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CRBP in your text
Paste any article, transcript, or post โ the tool will extract CRBP and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.